Paired Deep Mutational Scanning of Lck Activity and Inhibitor Sensitivity Enables the Engineering of Pharmacological Control of T Cell Receptor Signaling

Controlling signaling enzymes with small molecules is a central goal in chemical biology and is of great utility for engineering cell-derived immunotherapies. Yet strategies for conferring selective small-molecule sensitivity without disrupting a protein's native function remain limited. Here we present a generalizable approach to engineering small molecule-controlled multidomain protein kinases. Using deep mutational scanning of full-length Lck, a tyrosine kinase essential for T cell receptor (TCR) signaling, we measured the effect of nearly all single amino acid substitutions in the kinase domain on phosphotransferase activity. The resulting activity landscape defined the domain's tolerance to substitution, mapped the regulatory interfaces that tune phosphotransferase activity, and, by treating bulky substitutions as ligand proxies, nominated cryptic pockets where covalent liganding is predicted to allosterically inhibit Lck. In parallel screens, we measured the sensitization of each variant to five clinically approved, reversible drugs: dabrafenib, erlotinib, gefitinib, imatinib, and nilotinib. Together, these landscapes identified substitutions that preserved or enhanced activity while sensitizing Lck to inhibition. Sensitizing substitutions were distributed throughout the kinase domain, including positions more than 30 Å from the ATP-binding site, implicating long-range allosteric networks linking distal perturbations to ATP-binding site conformation and inhibitor potency. Integrating the activity and sensitization landscapes yielded a nilotinib-sensitized variant, I312S, that supports TCR signaling and, upon drug treatment, selectively suppresses proximal signaling and IL-2 production in Jurkat cells even in the presence of endogenous Lck.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-18
DOI
https://doi.org/10.64898/2026.11.13.766442
Primary Topic
Protein Kinase Regulation and GTPase Signaling
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Paired Deep Mutational Scanning of Lck Activity and Inhibitor Sensitivity Enables the Engineering of Pharmacological Control of T Cell Receptor Signaling

Melissa A. Chiasson, Cindy T. Wei, Dustin J. Maly, Zachary E. Potter et al.
bioRxiv (Cold Spring Harbor Laboratory)
Protein Kinase Regulation and GTPase Signaling
preprint

Paired Deep Mutational Scanning of Lck Activity and Inhibitor Sensitivity Enables the Engineering of Pharmacological Control of T Cell Receptor Signaling

Melissa A. Chiasson, Cindy T. Wei, Dustin J. Maly, Zachary E. Potter, Jordan L Brown, Jessica J. Simon, Daniel S Brush, Nicolas A Popp, Doria E Unrau, Jorge Cardenas, Amber N Graves, Douglas M Dowler
preprint en

Abstract

Controlling signaling enzymes with small molecules is a central goal in chemical biology and is of great utility for engineering cell-derived immunotherapies. Yet strategies for conferring selective small-molecule sensitivity without disrupting a protein's native function remain limited. Here we present a generalizable approach to engineering small molecule-controlled multidomain protein kinases. Using deep mutational scanning of full-length Lck, a tyrosine kinase essential for T cell receptor (TCR) signaling, we measured the effect of nearly all single amino acid substitutions in the kinase domain on phosphotransferase activity. The resulting activity landscape defined the domain's tolerance to substitution, mapped the regulatory interfaces that tune phosphotransferase activity, and, by treating bulky substitutions as ligand proxies, nominated cryptic pockets where covalent liganding is predicted to allosterically inhibit Lck. In parallel screens, we measured the sensitization of each variant to five clinically approved, reversible drugs: dabrafenib, erlotinib, gefitinib, imatinib, and nilotinib. Together, these landscapes identified substitutions that preserved or enhanced activity while sensitizing Lck to inhibition. Sensitizing substitutions were distributed throughout the kinase domain, including positions more than 30 Å from the ATP-binding site, implicating long-range allosteric networks linking distal perturbations to ATP-binding site conformation and inhibitor potency. Integrating the activity and sensitization landscapes yielded a nilotinib-sensitized variant, I312S, that supports TCR signaling and, upon drug treatment, selectively suppresses proximal signaling and IL-2 production in Jurkat cells even in the presence of endogenous Lck.

bioRxiv (Cold Spring Harbor Laboratory)
University of Washington (US)
Protein Kinase Regulation and GTPase Signaling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon